MEDICATION USE & BREAST CANCER IN A BIRACIAL POPULATION

药物使用

• 批准号: 2733134
• 负责人: Patricia G Moorman
• 金额: $ 11.18万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 2001-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2733134
• 关键词: African American; age difference; antidepressants; antioxidants; aspirin; breast neoplasms; cancer risk; caucasian American; clinical research; dietary supplements; drug related neoplasm /cancer; estrogens; female; hormone therapy; human data; human subject; neoplasm /cancer epidemiology; nonsteroidal antiinflammatory agent; nutrition related tag; oral contraceptives; progestins; racial /ethnic difference

DESCRIPTION: (Adapted from Applicant's Abstract). The objective of this FIRST award in epidemiology is to examine the role of several commonly used medications that may either increase (hormones, antidepressants) or decrease (nonsteroidal anti-inflammatory drugs (NSAIDs), anti-oxidants) the risk of breast cancer. The proposed studies will utilize the infrastructure established for a large, population-based, case-control study of breast cancer in North Carolina, the Carolina Breast Cancer Study (CBCS). The CBCS will have enrolled 800 cases and 800 controls by the end of its first phase in spring, 1996, and an additional 1600 participants will be recruited in its second phase. The study population will have approximately equal numbers of black and white women, allowing an evaluation of potential racial differences in the association of these medications and breast cancer risk. Information on hormone use and anti-oxidant consumption is currently being collected as part of a comprehensive questionnaire on breast cancer risk factors. Questions to assess the use of NSAIDs and antidepressants will be developed and added to the questionnaire used in the second phase of the CBCS. Analyses of the data will focus on hypotheses derived from preliminary investigations, including animal studies (i.e., NSAIDs' protective effect, and the antidepressants' tumor promotion effect) or questions that have remained unanswered due to temporal considerations (i.e., the risk of peri- and postmenopausal breast cancer among women who used oral contraceptives early in their reproductive years, and the risk among women who used both oral contraceptives and menopausal hormones). The investigation of the roles these medications play in the development of breast cancer is important for several reasons. Physicians and patients should know the potential adverse effects associated with a given therapy so they can make informed judgments of the benefits versus the risks. Because millions of women are prescribed hormones and antidepressants each year, even a model increase in risk could translate into a large number of breast cancers. For the medications with evidence suggestive of a protect effect, it is important.

描述：（改编自申请人的摘要）。 这个目的 流行病学上的第一个奖项是检查几个常用的角色 可能增加（激素，抗抑郁药）或减少的药物 （非甾体类抗炎药（NSAIDS），抗氧化剂） 乳腺癌。 拟议的研究将利用基础设施 为乳房的大型，基于人群的病例对照研究建立 卡罗来纳州乳腺癌研究（CBC）的北卡罗来纳州癌症。 CBCS 将在第一阶段结束时注册800例和800个对照 1996年春季，将招募另外1600名参与者 它的第二阶段。 研究人群将大致相等 黑白妇女的数量，可以评估潜在的种族 这些药物的关联和乳腺癌风险的差异。 目前正在有关激素使用和抗氧化剂消耗的信息 作为有关乳腺癌风险的综合问卷的一部分收集 因素。 评估NSAID和抗抑郁药的使用的问题将是 开发并添加到在第二阶段使用的问卷中 CBCS。 数据分析将集中于从中得出的假设 初步研究，包括动物研究（即NSAIDS' 保护作用，以及抗抑郁药的肿瘤促进作用）或 由于时间考虑的问题 （即，在妇女中，骨周围和绝经后乳腺癌的风险 在生殖年份的早期使用口服避孕药，风险 在使用口服避孕药和更年期激素的女性中）。 这 对这些药物在开发中发挥作用的作用的调查 乳腺癌很重要，原因有几个。 医师和患者 应该知道与给定疗法相关的潜在不良影响 他们可以对利益与风险做出明智的判断。 因为 每年有数百万妇女是处方的激素和抗抑郁药， 即使风险增加的模型也可能转化为大量乳房 癌症。 对于有证据表明保护作用的药物， 这很重要。